Loading
YB
Yield10 Bioscience, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Oct 2023.
Yield10 Bioscience, Inc.: what insiders have been doing
Yield10 Bioscience, Inc., classified in the Food & Agriculture sector, is a listed company based in Cambridge, United States, founded in 1992. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Yield10 Bioscience, Inc. in twelve months, the latest record being from 20 August 2024.
Our records for Yield10 Bioscience, Inc. go back to 2016, with 9 purchases and 6 sales on the open market in total.
In the same sector, recent insider purchases at Village Farms International, Inc. and Orkla ASA also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
60
Thresholds
n/a
Buy Volume
€1M
9 ops. · all time
Sell Volume
€61,809
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$51.7k
Net income-US$12.4M-24091.7% margin
Last declaration on 20 August 2024
Declarations60 total
877 shares@ US$1.501.8% of flowCommon StockSEC:0001628280-24-037879:0
731 shares@ US$1.501.7% of flowCommon StockSEC:0001104659-24-090983:0
1,463 shares@ US$1.500.9% of flowCommon StockSEC:0001104659-24-090981:0
731 shares@ US$1.501.5% of flowCommon StockSEC:0001104659-24-090982:0
36,000 shares@ US$0.200.5% of flowCommon StockSEC:0000908834-24-000148:0
11,924 shares0Common StockSEC:0001628280-24-013923:0
41,118 shares0Common StockSEC:0001628280-24-013917:0
20,561 shares0Common StockSEC:0001628280-24-013920:0
120,000 shares@ US$0.3049.8% of flowCommon StockSEC:0001628280-24-005491:0
200,000 shares@ US$0.3024.2% of flowCommon StockSEC:0001104659-24-025033:0
100,000 shares@ US$0.3043.0% of flowCommon StockSEC:0001104659-24-025035:0
100,000 shares@ US$0.3048.6% of flowCommon StockSEC:0001104659-24-025032:0
18,879 shares0Common StockSEC:0001628280-24-000210:0
16,275 shares0Common StockSEC:0001628280-24-000206:0
16,275 shares0Common StockSEC:0001628280-24-000203:0
36,000 shares@ US$0.20640.5% of flowCommon StockSEC:0000908834-23-000190:0
35,000 shares@ US$0.23770.5% of flowCommon StockSEC:0000908834-23-000181:0
765,000 shares@ US$0.6532.0% of flowCommon StockSEC:0000908834-23-000120:0
Canonical exit: 13 Nov 2023 (T+90)
41,399 shares@ US$0.31080.9% of flowCommon StockSEC:0000908834-23-000118:0
11,955 shares0Common StockSEC:0001121702-23-000058:0
13,868 shares0Common StockSEC:0001121702-23-000056:0
11,955 shares0Common StockSEC:0001121702-23-000054:0
2,040 shares0Common StockSEC:0001628280-23-024201:0
1,759 shares0Common StockSEC:0001628280-23-024197:0
1,759 shares0Common StockSEC:0001628280-23-024199:0
25 of 60 declarations
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc. (ticker: YTEN) is a United States agricultural bioscience company that was formerly listed on the Nasdaq Capital Market and was delisted in May 2024; its common stock subsequently became eligible for quotation on the OTC market under the YTEN symbol. For investors, this places the company in the small-cap, high-risk portion of the agribiotech universe, where valuation depends heavily on intellectual property, regulatory progress, and the ability to monetize technology through partnerships or licensing rather than on large-scale current revenues. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1121702/000110465924061645/tm2414256d2_ex99-1.htm?utm_source=openai))
The company traces its roots back to 1992, when it was founded as Metabolix with an MIT-related licensing background. It later rebranded as Yield10 Bioscience to reflect a strategic pivot toward agricultural innovation and crop-yield enhancement. Yield10 is headquartered in Woburn, Massachusetts, United States, and also operates through its Canadian subsidiary, Yield10 Oilseeds Inc., in Saskatoon, Saskatchewan. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1121702/000112170221000010/yten-20201231.htm?utm_source=openai))
Read moreShow less
Yield10’s core business centers on plant genetics and trait discovery through its proprietary “Trait Factory” platform, with Camelina sativa as the principal crop platform. The company is working to develop improved Camelina varieties and proprietary seed products aimed at low-carbon feedstock oils for renewable diesel and sustainable aviation fuel, omega-3 oils for aquafeed, nutrition and pharmaceutical applications, and, longer term, PHA biomaterials for biodegradable plastics. It also seeks to license yield-related traits to major seed companies for crops such as corn, soybean and canola. ([yield10bio.com](https://www.yield10bio.com/press/yield10-bioscience-announces-key-advancements-in-the-development-of-herbicide-tolerant-camelina-supporting-large-acreage-production-of-low-carbon-intensity-feedstock-oil-for-the-biofuel-market?utm_source=openai))
From a competitive standpoint, Yield10 occupies a narrow but potentially attractive niche. It is not a broad-acre agricultural input leader; instead, it competes on the quality of its genetic assets, field-validation data, and the commercial potential of Camelina as a platform crop. The investment case hinges on successfully moving from R&D to commercial adoption, securing regulatory clearances where needed, and converting scientific milestones into partner-funded commercialization. ([yield10bio.com](https://www.yield10bio.com/press/yield10-winter-camelina-proprietary-varieties-show-tolerance-commonly-used-herbicides?utm_source=openai))
Recent developments highlight both opportunity and financial strain. In July 2024, Yield10 announced an MOU and license agreement with Nuseed Nutritional US Inc. covering certain omega-3 intellectual property, materials and know-how related to Camelina, underscoring its partnership-led strategy. Earlier updates also emphasized herbicide-tolerant Camelina, seed scale-up, and commercial pathway work. At the same time, the Nasdaq delisting in 2024 marked an important negative event and suggests the company remains in a constrained financing environment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1121702/000112170224000055/exhibit991-ytenx20240712xx.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
